Kestra Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $353K | Buy |
1,084
+126
| +13% | +$41.1K | ﹤0.01% | 2225 |
|
|
2025
Q1 | $259K | Sell |
958
-629
| -40% | -$170K | ﹤0.01% | 2284 |
|
|
2024
Q4 | $373K | Buy |
1,587
+284
| +22% | +$66.8K | ﹤0.01% | 2065 |
|
|
2024
Q3 | $358K | Sell |
1,303
-88
| -6% | -$24.2K | ﹤0.01% | 1979 |
|
|
2024
Q2 | $338K | Buy |
1,391
+32
| +2% | +$7.78K | ﹤0.01% | 2039 |
|
|
2024
Q1 | $203K | Buy |
1,359
+91
| +7% | +$13.6K | ﹤0.01% | 2271 |
|
|
2023
Q4 | $243K | Buy |
+1,268
| New | +$243K | ﹤0.01% | 1986 |
|
|
2023
Q2 | – | Sell |
-1,066
| Closed | -$214K | – | 2104 |
|
|
2023
Q1 | $214K | Sell |
1,066
-1,272
| -54% | -$255K | ﹤0.01% | 1794 |
|
|
2022
Q4 | $556K | Buy |
2,338
+721
| +45% | +$171K | ﹤0.01% | 1353 |
|
|
2022
Q3 | $324K | Buy |
1,617
+201
| +14% | +$40.3K | ﹤0.01% | 1557 |
|
|
2022
Q2 | $207K | Buy |
1,416
+77
| +6% | +$11.3K | ﹤0.01% | 1876 |
|
|
2022
Q1 | $219K | Buy |
1,339
+74
| +6% | +$12.1K | ﹤0.01% | 1793 |
|
|
2021
Q4 | $215K | Sell |
1,265
-1,435
| -53% | -$244K | ﹤0.01% | 1834 |
|
|
2021
Q3 | $510K | Buy |
+2,700
| New | +$510K | 0.01% | 1379 |
|
|
2020
Q4 | – | Sell |
-67
| Closed | -$639K | – | 1849 |
|
|
2020
Q3 | $639K | Buy |
+67
| New | +$639K | 0.01% | 782 |
|